Actieve functies van Ping Zhu
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
H3 Biomedicine, Inc.
 H3 Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa. | Directeur/Bestuurslid | - | - |
| Hoofd Techniek/Wetenschap/O&O | 01-08-2021 | - | |
| President | 01-08-2021 | - | |
| Corporate Officer/Principal | 01-01-2012 | 30-08-2021 |
Loopbaan van Ping Zhu
Opleiding van Ping Zhu
| Shanghai Second Medical University | Undergraduate Degree |
| University of Karlsruhe | Doctorate Degree |
Statistieken
Internationaal
| Verenigde Staten | 2 |
| China | 2 |
| Duitsland | 2 |
Operationeel
| Director/Board Member | 1 |
| Chief Tech/Sci/R&D Officer | 1 |
| Corporate Officer/Principal | 1 |
Sectoraal
| Consumer Services | 3 |
| Health Technology | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Bedrijven in privébezit | 1 |
|---|---|
H3 Biomedicine, Inc.
H3 Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa. | Health Technology |
